dabrafenib + rifampin

This is a **combination of dabrafenib**, a selective inhibitor of BRAF V600-mutant kinases, with **rifampin**, a potent inducer of cytochrome P450 enzymes. **Dabrafenib** selectively inhibits mutant BRAF serine-threonine kinases involved in cell signaling and proliferation, particularly in cancers with BRAF V600 mutations. **Rifampin** is an antibiotic that acts by inhibiting bacterial DNA-dependent RNA polymerase but is also a strong inducer of several CYP450 isoenzymes, most notably CYP2C8 and CYP3A4. The combination is not used therapeutically as a fixed combination product; rather, the interaction is clinically significant: co-administration results in a **marked reduction of dabrafenib exposure** due to rifampin’s induction of CYP3A4 and CYP2C8 metabolism, potentially leading to loss of antineoplastic efficacy[1][2][4].

Brand names

Rifadin

Other names

dabrafenibrifampicin